Timolol Maleate: A Comprehensive Guide
Timolol Maleate is a non-selective beta-adrenergic receptor blocking agent used primarily as an ophthalmic solution to reduce elevated intraocular pressure associated with glaucoma and ocular hypertension.
Timolol maleate API is a white to off-white crystalline powder, slightly soluble in water and freely soluble in ethanol.
Timolol maleate is one of our GMP-approved pharmaceutical raw materials, along with Amphotericin B, Bacitracin, etc.
It can be administered orally or as eye drops.
When taken orally, it is used to treat hypertension.
Since timolol is available as eye drops, you can use it to treat glaucoma and ocular hypertension.
For decades, Timolol Maleate has served as a cornerstone in glaucoma management, a leading cause of irreversible blindness worldwide.
This comprehensive guide explores every aspect of the drug—from its fundamental mechanism of action to its critical role in fixed-dose combination therapies, its safety profile, and its position in the global active pharmaceutical ingredient (API) market.
Understanding this medication is vital for healthcare providers, patients, and industry professionals navigating the complex landscape of ocular and cardiovascular therapeutics.
What is Timolol Maleate? (Istalol)
Timolol Maleate is a potent non-selective beta-adrenergic receptor blocker.
In its ophthalmic formulation, it is typically supplied as a sterile, isotonic, buffered aqueous solution.
Each milliliter of a standard 0.5% ophthalmic solution contains 5 mg of timolol, which is equivalent to 6.8 mg of timolol maleate.
The solution maintains a pH of 6.5-7.5 and an osmolality of 275-330 mOsm/kg, ensuring comfort and compatibility with ocular tissues.
Common inactive ingredients include stabilizers, such as monobasic sodium phosphate, and preservatives, such as benzalkonium chloride 0.005%, which is added to prevent microbial contamination in multi-dose containers.
Patients are advised that soft contact lenses can absorb this preservative, so lenses should be removed before administration and reinserted no earlier than 15 minutes afterward.
Unlike some older glaucoma medications (miotics), Timolol Maleate reduces intraocular pressure with little to no effect on pupil size or the eye’s ability to focus (accommodation), making it more comfortable for many patients.
What Is Timolol Maleate Used For?
The primary and most well-established use of Timolol Maleate is in the management of ocular conditions characterized by elevated intraocular pressure (IOP).
Chronic Open-Angle Glaucoma and Ocular Hypertension: These are the core indications. Elevated IOP is a significant risk factor for glaucomatous visual field loss and optic nerve damage. Timolol is indicated to reduce this elevated pressure in patients with these conditions.
Other Glaucoma Types: It has also been shown to effectively reduce IOP in aphakic patients (those without a natural lens) with glaucoma, including those wearing contact lenses.
Angle-Closure Glaucoma: It is important to note that Timolol is not used alone in angle-closure glaucoma. The immediate goal in this emergency condition is to reopen the eye’s drainage angle by constricting the pupil with a miotic agent. Timolol, which has little effect on the pupil, can be combined with a miotic to help lower pressure, but should never be the sole therapy.
Prevention of Post-Procedural Pressure Spikes: Timolol, often in combination with other agents, is used prophylactically to prevent IOP spikes after certain ocular procedures, such as Neodymium-doped Yttrium Aluminum Garnet (Nd: YAG) laser capsulotomy for posterior capsule opacification.
Cardiovascular and Other Uses:
While its ophthalmic use is most common, Timolol’s systemic (oral) formulation is used to treat hypertension, manage certain cardiac arrhythmias, and improve survival after a heart attack.
Its utility in treating infantile hemangiomas has also been explored, leveraging its effect on blood vessels.
How Does Timolol Maleate Work? (Mechanism of Action)
Timolol Maleate works by non-selectively blocking beta-adrenergic receptors.
It inhibits both beta-1 (primarily cardiac) and beta-2 (mainly pulmonary and vascular) receptors, without significant intrinsic sympathomimetic activity (i.e., it doesn’t partially stimulate the receptors it blocks).
In the Eye: The precise mechanism by which IOP is lowered remains unclear. Still, the predominant action is believed to be the reduction of aqueous humor production by the ciliary body.
Some studies also suggest a slight increase in the outflow facility (improved drainage) of the aqueous humor.
Reducing fluid input to the eye lowers overall pressure.
Systemic Effects: The systemic absorption of topical timolol, though minimal, can lead to potential side effects and contraindications.
Beta-blockade reduces heart rate and cardiac output.
In the lungs, it can increase airway resistance by blocking the bronchodilating effect of endogenous catecholamines, which is why it is dangerous for patients with asthma.
Timolol Maleate Dosage and Administration
Proper administration is key to efficacy and safety.
Standard Dosage: For the 0.25% or 0.5% ophthalmic solution, the typical dose is one drop in the affected eye(s) twice a day.
Long-Acting Formulations: Gel-forming solutions (e.g., TIMOLOL MALEATE-EX) are designed for once-daily administration, thereby significantly improving patient adherence. The NHS formulary notes there is no evidence that the 0.5% strength is more effective than the 0.25% strength, and thus may prefer the lower concentration.
Critical Administration Instructions:
Wash your hands before use.
Tilt your head back, pull down the lower eyelid to form a pouch.
Avoid letting the tip of the bottle come into contact with the eye, fingers, or any surface to prevent contamination, which can lead to serious eye infections.
If using multiple eye drops, wait at least 10 minutes between applications.
Do not abruptly stop using Timolol. When switching from another glaucoma medication, the old drug should be gradually phased out starting on the second day of Timolol therapy.
Storage: Keep the bottle tightly closed and store as directed. Once opened, most solutions should not be used for more than one month.
What Are the Side Effects of Timolol Maleate?
Timolol is generally well-tolerated, but side effects can occur.
Common Ocular Effects: Transient eye burning or stinging, conjunctival irritation, dry eyes, and blurred vision (especially with gel-forming solutions).
Serious Systemic Effects (due to absorption): These are less common but require immediate medical attention:
Cardiovascular: Slow heart rate (bradycardia), heart palpitations, heart block, worsening of heart failure, low blood pressure, and fainting.
Respiratory: Shortness of breath, bronchospasm (especially in susceptible individuals), and respiratory failure.
Neurological/Psychiatric: Dizziness, headache, depression, and increased fatigue.
Other Potential Reactions: Rash, hair loss (alopecia), and taste disturbances.
Patients should be instructed to promptly report any unusual symptoms, particularly difficulty breathing, slowed pulse, dizziness, or depression, to their healthcare provider.
Timolol Maleate Precautions and Drug Interactions
Due to systemic absorption, Timolol eye drops carry important precautions similar to oral beta-blockers.
Absolute Contraindications: Timolol is strictly forbidden in patients with:
Bronchial asthma or a history of it.
Severe chronic obstructive pulmonary disease (COPD).
Sinus bradycardia, 2nd/3rd degree heart block, or overt cardiac failure.
Cardiogenic shock.
Hypersensitivity to any component.
Major Drug Interactions:
Systemic Beta-Blockers: Concomitant use can potentiate systemic beta-blockade effects (severe bradycardia, heart failure).
Calcium Channel Blockers (e.g., verapamil): Can cause excessive lowering of blood pressure, heart failure, or conduction abnormalities. Oral beta-blocker eye drops should be avoided in patients on oral verapamil.
Catecholamine-Depleting Drugs (e.g., reserpine): May lead to additive effects causing hypotension and/or marked bradycardia.
Quinidine: Potentiates systemic beta-blockade, significantly decreasing heart rate.
Epinephrine (Adrenaline): Timolol may blunt the beta-adrenergic effects of epinephrine, reducing its effectiveness for treating anaphylaxis in patients on Timolol. Alternative anaphylaxis treatments should be considered.
Special Populations:
Pregnancy & Lactation: Use only if the potential benefit justifies the potential risk to the fetus. Timolol is excreted in breast milk, so caution is advised.
Diabetes: May mask the signs of acute hypoglycemia (like tachycardia).
Myasthenia gravis may increase muscle weakness.
Major Surgery: Beta-blockade can impair the heart’s response to reflex stimuli. The decision to withdraw therapy before elective surgery is controversial and should be made by the anesthesia and surgical team.
How Long Does Timolol Maleate Take to Work?
Timolol has a relatively rapid onset of action.
The reduction in intraocular pressure can usually be detected within 30 minutes after a single dose.
The maximum pressure-lowering effect typically occurs between 1 and 2 hours after administration.
A significant therapeutic effect can be maintained for up to 24 hours with a single dose, supporting its use in both twice-daily and once-daily long-acting regimens.
Long-term studies confirm that the intraocular pressure-lowering effect is well maintained for at least 1 year of continuous use, providing sustained protection against glaucomatous damage.
Dorzolamide Hydrochloride and Timolol Maleate
The fixed-dose combination of Dorzolamide (a carbonic anhydrase inhibitor) and Timolol Maleate (DTFC) is a mainstay of glaucoma therapy, marketed under the brand name Cosopt®.
The combination offers a synergistic mechanism: Timolol reduces aqueous production, and Dorzolamide further suppresses it by a different biochemical pathway.
Clinical Efficacy and Role:
DTFC is widely prescribed globally, often as an adjunctive therapy when prostaglandin analog monotherapy does not sufficiently lower IOP.
A 2023 multicenter crossover study (the Aibeta Crossover Study) found that adding DTFC to a prostaglandin regimen reduced IOP by 3.60 mmHg over 8 weeks.
It is particularly noted for its potent pressure-lowering effect.
Tolerability Considerations:
The primary drawback of the DTFC combination is ocular discomfort.
The same 2023 study reported that patients experienced significantly greater discomfort during DTFC instillation than with a brimonidine/timolol combination (BTFC).
This burning or stinging sensation, attributed to the dorzolamide component, can impact patient adherence.
Therefore, while highly effective, DTFC may be more appropriate when maximum IOP reduction is the primary concern and the patient can tolerate the discomfort.
Brimonidine Tartrate and Timolol Maleate
The fixed-dose combination of Brimonidine Tartrate (an alpha-2 adrenergic agonist) and Timolol Maleate (BTFC), marketed as Combigan® or Aibeta®, represents another powerful two-pronged approach.
Brimonidine lowers IOP by both reducing aqueous production and increasing uveoscleral outflow.
Clinical Performance vs. DTFC:
Modern comparative studies show BTFC is a formidable alternative.
The 2023 Aibeta Crossover Study demonstrated that BTFC was non-inferior to DTFC in IOP reduction when added to a prostaglandin, lowering pressure by 3.55 mmHg.
Crucially, the study found that patients reported significantly less ocular discomfort with BTFC and overwhelmingly preferred it over DTFC.
Therapeutic Niche:
Due to its excellent tolerability and comparable efficacy, BTFC is increasingly recommended as a first-choice adjunctive therapy or as an alternative for patients who experience significant irritation from dorzolamide-containing drops.
Its side-effect profile is similar to the DTFC combination, though it may be less likely to cause certain symptoms, such as watery eyes.
*Table 1: Comparison of Timolol Maleate Fixed-Dose Combinations*
| Feature | Dorzolamide/Timolol (DTFC) | Brimonidine/Timolol (BTFC) |
|---|---|---|
| Brand Examples | Cosopt® | Combigan®, Aibeta® |
| Secondary Agent Class | Carbonic Anhydrase Inhibitor | Alpha-2 Adrenergic Agonist |
| Key Mechanism | Reduces aqueous production | Reduces production & increases outflow |
| Typical IOP Reduction (as an adjunct) | ~3.60 mmHg | ~3.55 mmHg |
| Patient Tolerability | Lower, frequent burning/stinging | Higher, preferred by patients |
| Primary Consideration | Potent IOP control | Excellent balance of efficacy & comfort |
Is Timolol Maleate safe for transport by air?
Between 2019 and 2022, it was tested and found to be a non-hazardous chemical suitable for air transportation.
Because the testing results from authorities change every year, and although we are not 100% sure we can get a certificate for safe air transportation from authorities in future years, we are still pretty optimistic that it is safe to ship it by air.
What is the HS code for Timolol Maleate?
(S)-timolol maleate is the maleic acid salt of the active (S)-enantiomer of timolol, with a ratio of (S)-timolol and maleic acid as 1:1.
In China Customs, it is classified as an organic compound in the class of other heterocyclic compounds, with HS code 29349990.
How Much Does Bulk Timolol Maleate API Cost?
Our FOB Beijing/Shanghai price for GMP-compliant bulk Timolol maleate API is about 2000 USD/KG.
For pricing on commercial order quantities, please contact us directly for the latest quotation.
For non-GMP grades, the price is lower.
To get the latest cost, please contact us directly for a price update.
Global Sourcing Tips for Timolol Maleate API
The Timolol Maleate Active Pharmaceutical Ingredient (API) market is a significant segment of the global pharmaceutical industry, driven by the high prevalence of glaucoma and cardiovascular diseases.
Market Overview: The market was valued at approximately $450 million in 2024 and is projected to grow steadily, reaching around $650 million by 2033. North America is the largest regional market, followed by Europe and the fast-growing Asia-Pacific region.
Sourcing Considerations:
Quality & Compliance: Prioritize suppliers with robust GMP (Good Manufacturing Practice) certification and a proven track record of passing inspections by stringent regulatory bodies such as the FDA and EMA.
Supply Chain Resilience: The COVID-19 pandemic underscored the need for diversified sourcing. Evaluate suppliers for redundant manufacturing sites and transparent supply chains to mitigate risk.
Documentation: Ensure complete Regulatory Support Files (RSF) and Drug Master Files (DMF) are available and in good standing with target market authorities.
Strategic Partnerships: For long-term security, consider moving beyond transactional relationships to strategic partnerships with key suppliers, which can offer better priority, pricing stability, and collaborative development.
Table 2: Timolol Maleate API Market at a Glance
| Aspect | Detail |
|---|---|
| 2024 Market Value | ~$450 Million USD |
| 2033 Projection | ~$650 Million USD |
| Key Growth Driver | Rising prevalence of glaucoma & hypertension |
| Largest Regional Market (2023) | North America (~40% share) |
| Fastest Growing Region | Asia-Pacific |
| Dominant Application | Ophthalmic Solutions (>70% of revenue) |
| Example Suppliers | Teva API, etc |
Conclusion
Timolol Maleate remains an indispensable player in modern medicine, particularly in the fight against glaucoma.
Its effectiveness, rooted in its non-selective beta-blockade mechanism, has stood the test of time.
The development of fixed-dose combinations of dorzolamide and brimonidine has further solidified their role, enabling enhanced efficacy and more tailored treatment by balancing pressure control and patient comfort.
While generally safe, it carries a risk of systemic side effects, necessitating careful patient selection and education. From a global perspective, the Timolol Maleate API market reflects ongoing, growing demand for this critical medication.
Whether you are a clinician prescribing it, a patient using it, or a professional involved in its manufacture and supply, a deep understanding of Timolol Maleate—encompassing its science, its clinical applications, and its economic context—is essential for optimizing outcomes and navigating the future of ocular healthcare.
Disclaimer:
This content is for informational purposes only and is intended for business-to-business communication within the pharmaceutical industry. It is not intended as medical advice. The manufacture, import, and use of API must comply with all applicable laws and regulations in the relevant country or region.
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
